Photopheresis: Advances and Use in Systemic Sclerosis

Scleroderma (J Varga, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Scleroderma

Abstract

Purpose of Review

Extracorporeal photochemotherapy (photopheresis, ECP) is a cell-based immunomodulatory treatment that separates leukocytes from peripheral blood, exposes them to a photosensitizing agent followed by ultraviolet A light, and then reinfuses them back into the patient. ECP has been found to be effective for graft versus host disease, transplant rejection, and various autoimmune diseases. The mechanism is not well understood but studies have shown clinical benefit in the treatment of systemic sclerosis (SSc). This review examines the ECP technique, advances in our knowledge of its mechanism, and the data supporting its use in SSc-like fibrosing diseases and in SSc itself.

Recent Findings

Multiple lines of evidence support ECP use in SSc. ECP generates apoptotic cells and dendritic cells, induces production of anti-inflammatory cytokines, and increases regulatory T cell numbers. Clinical studies have generally demonstrated improvement, especially the skin, in SSc patients receiving ECP.

Summary

ECP may be an effective and safe procedure for the treatment of SSc.

Keywords

Systemic sclerosis SSc Scleroderma Extracorporeal photopheresis ECP Extracorporeal photochemotherapy 

References

Papers of particular, published recently interest, have been highlighted as: • Of importance

  1. 1.
    Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. Int J Mol Sci. 2013;14(3):6414–35.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy preliminary results. N Engl J Med. 1987;316(6):297–303.CrossRefPubMedGoogle Scholar
  3. 3.
    Decision Memo for Extracorporeal Photopheresis (ECP) (CAG-00324R2). https://http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=255. Accessed 23 Jan 2017.
  4. 4.
    Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107(8):3074–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol. Feb 2009;145(2):127–30.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pileri A, Raone B, Raboni R, Giudice V, Patrizi A. Generalized morphea successfully treated with extracorporeal photochemotherapy (ECP). Dermatol Online J. 2014;20(1):21258.PubMedGoogle Scholar
  7. 7.
    Schlaak M, Friedlein H, Kauer F, Renner R, Rogalski C, Simon JC. Successful therapy of a patient with therapy recalcitrant generalized bullous scleroderma by extracorporeal photopheresis and mycophenolate mofetil. J Eur Acad Dermatol Venereol. 2008;22(5):631–3.CrossRefPubMedGoogle Scholar
  8. 8.
    Pileri A, Odorici G, Giudice V, Patrizi A, Bardazzi F. Bosentan and extracorporeal photochemotherapy in eosinophilic fasciitis: synergistic action or fortuitous coincidence? Int J Low Extrem Wounds. 2014;13(2):160–1.CrossRefPubMedGoogle Scholar
  9. 9.
    Romano C, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol. 2003;17(1):10–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Di Spaltro FX, Cottrill C, Cahill C, et al. Extracorporeal photochemotherapy in progressive systemic sclerosis. Int J Dermatol. 1993;32(6):417–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Fimiani M, Rubegni P, Flori ML, Mazzatenta C, D'Ascenzo G, Andreassi L. Three cases of progressive systemic sclerosis treated with extracorporeal photochemotherapy. Arch Dermatol Res. 1997;289(2):120–2.CrossRefPubMedGoogle Scholar
  12. 12.
    • Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(Suppl 1):1–37. This article provides the most comprehensive available expert recommendations from the European Dermatology Forum on the use of extracorporeal photopheresis based on published literature and expert consensus opinion CrossRefPubMedGoogle Scholar
  13. 13.
    Krasagakis K, Dippel E, Ramaker J, Owsianowski M, Orfanos CE. Management of severe scleroderma with long-term extracorporeal photopheresis. Dermatology. 1998;196(3):309–15.CrossRefPubMedGoogle Scholar
  14. 14.
    Papp G, Horvath IF, Barath S, et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol. Feb 2012;142(2):150–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Reich S, Gambichler T, Altmeyer P, Kreuter A. Extracorporeal photopheresis in systemic sclerosis: effects on organ involvement? J Am Acad Dermatol. Feb 2007;56(2):348–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. Arch Dermatol. Mar 1992;128(3):337–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Liszewski W, Omland SH, Gniadecki R. The successful use of extracorporeal photopheresis in a 12-year-old patient with refractory epidermolysis bullosa acquisita. Pediatr Dermatol. 2015;32(2):e60–1.CrossRefPubMedGoogle Scholar
  18. 18.
    Elewa R, Altenburg A, Zouboulis CC. Recalcitrant severe erosive cutaneous lichen planus treated with extracorporeal photopheresis monotherapy. Br J Dermatol. 2011;165(2):441–3.CrossRefPubMedGoogle Scholar
  19. 19.
    Gollnick HP, Owsianowski M, Taube KM, Orfanos CE. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol. 1993;28(1):122–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol. 1992;26(5 Pt 1):779–80.CrossRefPubMedGoogle Scholar
  21. 21.
    Rook AH. Photopheresis in the treatment of autoimmune disease: experience with pemphigus vulgaris and systemic sclerosis. Ann N Y Acad Sci. 1991;636:209–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Vonderheid EC, Kang CA, Kadin M, Bigler RD, Griffin TD, Rogers TJ. Extracorporeal photopheresis in psoriasis vulgaris: clinical and immunologic observations. J Am Acad Dermatol. 1990;23(4 Pt 1):703–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Vonderheid EC, Bigler RD, Rogers TJ, Kadin ME, Griffin TD. Effect of extracorporeal photopheresis on selected immunologic parameters in psoriasis vulgaris. Yale J Biol Med. 1989;62(6):653–64.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Akay BN, Sanli H, Kutlay S. Treatment of ankylosing spondylitis by extracorporeal photochemotherapy given for mycosis fungoides: a potential treatment option? J Clin Rheumatol. 2011;17(5):278–80.CrossRefPubMedGoogle Scholar
  25. 25.
    Malawista SE, Trock DH, Edelson RL. Treatment of rheumatoid arthritis by extracorporeal photochemotherapy. A pilot study. Arthritis Rheum. 1991;34(6):646–54.CrossRefPubMedGoogle Scholar
  26. 26.
    Berkson M, Lazarus GS, Uberti-Benz M, Rook AH. Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol. 1991;25(4):724.CrossRefPubMedGoogle Scholar
  27. 27.
    Knobler RM, Graninger W, Lindmaier A, Trautinger F. Photopheresis for the treatment of lupus erythematosus. Preliminary observations. Ann N Y Acad Sci. 1991;636:340–56.CrossRefPubMedGoogle Scholar
  28. 28.
    Koppelhus U, Poulsen J, Grunnet N, Deleuran MS, Obitz E. Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross-over study comparing two efficient treatment modalities. Front Med (Lausanne). 2014;1:33.Google Scholar
  29. 29.
    Radenhausen M, Michelsen S, Plewig G, Bechara FG, Altmeyer P, Hoffmann K. Bicentre experience in the treatment of severe generalised atopic dermatitis with extracorporeal photochemotherapy. J Dermatol. 2004;31(12):961–70.CrossRefPubMedGoogle Scholar
  30. 30.
    Cavaletti G, Perseghin P, Dassi M, et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. Neurol Sci. 2006;27(1):24–32.CrossRefPubMedGoogle Scholar
  31. 31.
    Besnier DP, Chabannes D, Mussini JM, Dupas B, Esnault VL. Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol Photoimmunol Photomed. 2002;18(1):36–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Rostami AM, Sater RA, Bird SJ, et al. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler. 1999;5(3):198–203.CrossRefPubMedGoogle Scholar
  33. 33.
    Fowler S, Jones J, Hull PR, Ghosh S. Extracorporeal photopheresis for the treatment of Crohn’s disease. Transfus Apher Sci. 2015;52(2):183–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Cheerva A, Dillard R, Bertolone S. Extracorporeal photopheresis for the treatment of severe, refractory steroid dependent pediatric Crohn’s disease. J Clin Apher. 2013;28(5):381–6.PubMedGoogle Scholar
  35. 35.
    Reinisch W, Knobler R, Rutgeerts PJ, et al. Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn’s disease: an open-label, multicenter, prospective trial. Inflamm Bowel Dis. 2013;19(2):293–300.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Abreu MT, von Tirpitz C, Hardi R, et al. Extracorporeal photopheresis for the treatment of refractory Crohn’s disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009;15(6):829–36.CrossRefPubMedGoogle Scholar
  37. 37.
    Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child. 2001;85(2):149–54.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Find an ECP Treatment Center in the United States and Canada. http://www.therakos.com/treatment-center-locator. Accessed January 23, 2017.
  39. 39.
    Therakos Photopheresis Immunotherapy. http://www.therakos.com/therakos-photopheresis-immunotherapy. Accessed 23 Jan 2017.
  40. 40.
    Sokhn JG, Choi J, Foss FM. Photopheresis. In: Wingard JR, Gastineau DA, Leather HL, Snyder EL, Szczepiorkowski ZM, eds. Hematopoietic stem cell transplantation: a handbook for clinicians. 2nd edition. ed. Bethesda, MD: AABB; 2014.Google Scholar
  41. 41.
    UVADEX. Full Prescribing Information. http://www.therakos.co.uk/full-prescribing-information. Accessed January 24, 2017.
  42. 42.
    "THERAKOS® CELLEX® Photopheresis System: Operator's Manual". Technical Bulletin #18 Rev B: 1460033_EN-US ed: Therakos, Inc; 2014.Google Scholar
  43. 43.
    Klassen J. The role of photopheresis in the treatment of graft-versus-host disease. Curr Oncol. 2010;17(2):55–8.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Rangarajan HG, Punzalan RC, Camitta BM, Talano JA. The use of novel Therakos Cellex(R) for extracorporeal photopheresis in treatment of graft-versus-host disease in paediatric patients. Br J Haematol. 2013;163(3):357–64.CrossRefPubMedGoogle Scholar
  45. 45.
    Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17(1):1–17.CrossRefGoogle Scholar
  46. 46.
    Matsumura Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine. Expert Rev Mol Med. 2002;4(26):1–22.CrossRefPubMedGoogle Scholar
  47. 47.
    Knobler RM, Trautinger F, Graninger W, et al. Parenteral administration of 8-methoxypsoralen in photopheresis. J Am Acad Dermatol. 1993;28(4):580–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Hart JW, Shiue LH, Shpall EJ, Alousi AM. Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion. Therapeutic advances in hematology. 2013;4(5):320–34.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Schneiderman J, Jacobsohn DA, Collins J, Thormann K, Kletzel M. The use of fluid boluses to safely perform extracorporeal photopheresis (ECP) in low-weight children: a novel procedure. J Clin Apher. 2010;25(2):63–9.PubMedGoogle Scholar
  50. 50.
    Uygun V, Daloglu H, Karasu G, Hazar V, Yesilipek A. Safety and outcomes of extracorporeal photopheresis with the Therakos Cellex System for graft-versus-host disease in pediatric patients. J Pediatr Hematol Oncol. Apr 2015;37(3):209–14.CrossRefPubMedGoogle Scholar
  51. 51.
    Berger C, Hoffmann K, Vasquez JG, et al. Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy. Blood. 2010;116(23):4838–47.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    • Edelson RL. Mechanistic insights into extracorporeal photochemotherapy: efficient induction of monocyte-to-dendritic cell maturation. Transfus Apher Sci. 2014;50(3):322–9. This article provides mechanistic insights from one of the founding fathers of ECP, who discusses ECP’s generation of dendritic cells and its immunomodulatory effects CrossRefPubMedGoogle Scholar
  53. 53.
    Choi J, Heald PW, Girardi M. Extracorporeal photochemotherapy (photopheresis). In: Wolverton SE, ed. Comprehensive dermatologic drug therapy. 3rd ed 2012:291–298.Google Scholar
  54. 54.
    Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol. 2008;8(5):327–36.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Lemke G, Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Ann N Y Acad Sci. 2010;1209:23–9.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Xia CQ, Campbell KA, Clare-Salzler MJ. Extracorporeal photopheresis-induced immune tolerance: a focus on modulation of antigen-presenting cells and induction of regulatory T cells by apoptotic cells. Curr Opin Organ Transplant. 2009;14(4):338–43.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    • Li H, Shi B. Tolerogenic dendritic cells and their applications in transplantation. Cellular & molecular immunology. 2015;12(1):24–30. This article discusses current knowledge of tolerogenic dendritic cells and their immune effects CrossRefGoogle Scholar
  58. 58.
    Capitini CM, Davis JP, Larabee SM, Herby S, Nasholm NM, Fry TJ. Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow-derived interleukin-10 and preserves responses to dendritic cell vaccination. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011;17(6):790–9.CrossRefGoogle Scholar
  59. 59.
    Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7(8):610–21.CrossRefPubMedGoogle Scholar
  60. 60.
    Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007;84(1):31–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112(4):1515–21.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Maeda A, Schwarz A, Bullinger A, Morita A, Peritt D, Schwarz T. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: generation of IL-10 and induction of regulatory T cells. J Immunol. 2008;181(9):5956–62.CrossRefPubMedGoogle Scholar
  63. 63.
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–64.PubMedGoogle Scholar
  64. 64.
    Sojka DK, Huang YH, Fowell DJ. Mechanisms of regulatory T-cell suppression–a diverse arsenal for a moving target. Immunology. 2008;124(1):13–22.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol. 2005;174(10):5968–76.CrossRefPubMedGoogle Scholar
  66. 66.
    George JF, Gooden CW, Guo L, Kirklin JK. Role for CD4(+)CD25(+) T cells in inhibition of graft rejection by extracorporeal photopheresis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2008;27(6):616–22.CrossRefGoogle Scholar
  67. 67.
    Meloni F, Cascina A, Miserere S, Perotti C, Vitulo P, Fietta AM. Peripheral CD4(+)CD25(+) TREG cell counts and the response to extracorporeal photopheresis in lung transplant recipients. Transplant Proc. 2007;39(1):213–7.CrossRefPubMedGoogle Scholar
  68. 68.
    Lamioni A, Carsetti R, Legato A, et al. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation. 2007;83(10):1393–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Denney HA, Whittle RJ, Lai J, Jacques RM, Taylor PC. Regulatory T cells in chronic graft-versus-host disease after extracorporeal photopheresis: correlation with skin and global organ responses, and ability to taper steroids. Transplantation. 2017;101(1):204–11.CrossRefPubMedGoogle Scholar
  70. 70.
    Ward DM. Extracorporeal photopheresis: how, when, and why. J Clin Apher. 2011;26(5):276–85.CrossRefPubMedGoogle Scholar
  71. 71.
    O'Reilly S, Hugle T, van Laar JM. T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford). 2012;51(9):1540–9.CrossRefGoogle Scholar
  72. 72.
    Papp G, Horvath IF, Barath S, et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol. 2011;40(3):205–10.CrossRefPubMedGoogle Scholar
  73. 73.
    Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009;4(6):e5903.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    • Yang X, Yang J, Xing X, Wan L, Li M. Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014;16(1):R4. This study provides evidence that Th17 is involved in the pathogenesis of systemic sclerosis CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    • Slobodin G, Rimar D. Regulatory T Cells in Systemic Sclerosis: a Comprehensive Review. Clin Rev Allergy Immunol. 2016. This article discusses the controversial role of regulatory T cells in systemic sclerosis.Google Scholar
  76. 76.
    Liu X, Gao N, Li M, et al. Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction. PLoS One. 2013;8(6):e64531.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Slobodin G, Ahmad MS, Rosner I, et al. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol. 2010;261(2):77–80.CrossRefPubMedGoogle Scholar
  78. 78.
    Jiang N, Li M, Zeng X. Correlation of Th17 cells and CD4(+)CD25(+) regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin Med J. 2014;127(20):3557–61.PubMedGoogle Scholar
  79. 79.
    Klein S, Kretz CC, Ruland V, et al. Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis. 2011;70(8):1475–81.CrossRefPubMedGoogle Scholar
  80. 80.
    Antiga E, Quaglino P, Bellandi S, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol. 2010;162(5):1056–63.CrossRefPubMedGoogle Scholar
  81. 81.
    Fenoglio D, Battaglia F, Parodi A, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol. 2011;139(3):249–57.CrossRefPubMedGoogle Scholar
  82. 82.
    Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore). 2002;81(2):139–53.CrossRefGoogle Scholar
  83. 83.
    Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore). 2002;81(2):154–67.CrossRefGoogle Scholar
  84. 84.
    Cribier B, Faradji T, Le Coz C, Oberling F, Grosshans E. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology. 1995;191(1):25–31.CrossRefPubMedGoogle Scholar
  85. 85.
    Enomoto DN, Mekkes JR, Bossuyt PM, et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol. 1999;41(6):915–22.CrossRefPubMedGoogle Scholar
  86. 86.
    Knobler RM, French LE, Kim Y, et al. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. J Am Acad Dermatol. 2006;54(5):793–9.CrossRefPubMedGoogle Scholar
  87. 87.
    Muellegger RR, Hofer A, Salmhofer W, Soyer HP, Kerl H, Wolf P. Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis. An Austrian single-center study. Photodermatol Photoimmunol Photomed. 2000;16(5):216–23.CrossRefPubMedGoogle Scholar
  88. 88.
    Schwartz J, Winters JL, Padmanabhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. Jul 2013;28(3):145–284.CrossRefPubMedGoogle Scholar
  89. 89.
    Guideline on Extracoporeal Photopheresis. European Dermatology Forum; 2013. http://www.euroderm.org/edf/index.php/edf-guidelines/category/5-guidelines-miscellaneous?download=39:guideline-extracorporeal-photopheresis. Accessed 1 Mar 2017.

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of DermatologyNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of Biochemistry and Molecular GeneticsNorthwestern University Feinberg School of MedicineChicagoUSA
  3. 3.Robert H. Lurie Comprehensive Cancer CenterNorthwestern UniversityChicagoUSA

Personalised recommendations